Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose intranasal oxytocin crossover study in adults with autism spectrum disorder
2014-005452-26Phase 2Completed
- Sponsor
- OptiNose
- Start
- Dec 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin in Autism Spectrum Disorder (ASD) (3 arms), sponsored by OptiNose. Primary endpoint: Primary efficacy endpoint. Started Dec 2014; status: completed.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2014-005452-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005452-26.